Immunological Aspects of Approved MS Therapeutics

Immunological Aspects of Approved MS Therapeutics

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-rem...

Full description

Bibliographic Details
Main Authors: Paulus S. Rommer, Ron Milo, May H. Han, Sammita Satyanarayan, Johann Sellner, Larissa Hauer, Zsolt Illes, Clemens Warnke, Sarah Laurent, Martin S. Weber, Yinan Zhang, Olaf Stuve
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
immunotherapeutics
immunomodulation
immunosuppression
monoclonal antibodies
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01564/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01564/full

Similar Items